Pick manipulates crossing site to dislodge clots

Coronado, CA—Transvitreal limited arteriovenous manipulation (LAM) without vitrectomy appears to be safe and effective for resolving hemorrhage and improving vision in carefully selected eyes with complicated branch retinal vein occlusion (BRVO), said Rohit R. Lakhanpal, MD, at the annual meeting of the American Society of Retinal Specialists.

Related Videos
Related Content

Bausch + Lomb, Novaliq publish pivotal Phase 3 data on NOV03

March 23rd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Cataract surgery reimbursements may not be enough for some patients

March 23rd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Aurion Biotech receives approval from Japan’s PMDA for New Drug Application

March 23rd 2023

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

Bausch + Lomb, Novaliq publish pivotal Phase 3 data on NOV03

March 23rd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Cataract surgery reimbursements may not be enough for some patients

March 23rd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Aurion Biotech receives approval from Japan’s PMDA for New Drug Application

March 23rd 2023

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

Bausch + Lomb, Novaliq publish pivotal Phase 3 data on NOV03

March 23rd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Cataract surgery reimbursements may not be enough for some patients

March 23rd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Aurion Biotech receives approval from Japan’s PMDA for New Drug Application

March 23rd 2023

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.